Skip to content
2000
image of Needle-Free Future: Revolutionizing Immunization with Vaccine Creams

Abstract

For centuries, injections have been the primary method for vaccination; however, these traditional approaches present challenges due to pain, fear, and difficulties in administration. Scientists from Stanford University have developed vaccine creams, representing a revolutionary approach to the field of vaccination. Genetically modified forms the basis of these cream products, which support skin-based, painless vaccination without invasive procedures, while playing an essential role in the immune response. Scientists using tetanus as a test subject have obtained positive data from animal studies demonstrating effective immune responses to vaccination, indicating potential future applications for treating diseases, such as influenza, COVID-19, and cancer. Vaccination creams outperform classic injections in several ways, as they eliminate needle-related concerns while reducing adverse reactions, streamlining mass vaccination programs, and making the delivery of immunizations simpler, especially for populations that lack regular access to healthcare. Several key barriers continue to hinder the development of vaccine creams, including regulatory hurdles, stability concerns, production scalability, and public acceptance. Research discusses how vaccine creams revolutionize immunization processes by improving treatment accessibility, affordability, and broader acceptance rates.

Loading

Article metrics loading...

/content/journals/raddf/10.2174/0126673878398533250825152040
2025-08-29
2025-11-16
Loading full text...

Full text loading...

References

  1. Severn M.M. Horswill A.R. Staphylococcus epidermidis and its dual lifestyle in skin health and infection. Nat. Rev. Microbiol. 2023 21 2 97 111 10.1038/s41579‑022‑00780‑3 36042296
    [Google Scholar]
  2. Goldman B. Stanford scientists transform ubiquitous skin bacterium into a topical vaccine. 2025
    [Google Scholar]
  3. Speziale P. Pietrocola G. Monoclonal antibodies targeting surface-exposed and secreted proteins from staphylococci. Vaccines 2021 9 5 459 10.3390/vaccines9050459 34064471
    [Google Scholar]
  4. Miller L.S. Fowler V.G. Shukla S.K. Rose W.E. Proctor R.A. Development of a vaccine against Staphylococcus aureus invasive infections: Evidence based on human immunity, genetics and bacterial evasion mechanisms. FEMS Microbiol. Rev. 2020 44 1 123 153 10.1093/femsre/fuz030 31841134
    [Google Scholar]
  5. Sokolovska L. Isaguliants M. Buonaguro F.M. Proceedings of the online conference "vaccines and vaccination during and post covid pandemics" (7-9 December 2022). Vaccines 2023 11 7 1175 10.3390/vaccines11071175 37514990
    [Google Scholar]
  6. Needle-Free vaccines: stanford researchers develop topical vaccine cream using skin bacteria. 2024
    [Google Scholar]
  7. Nguyen HX Vaccine Administration 2024
    [Google Scholar]
  8. Harris C.T. Cohen S. Reducing immunogenicity by design: approaches to minimize immunogenicity of monoclonal antibodies. BioDrugs 2024 38 2 205 226 10.1007/s40259‑023‑00641‑2 38261155
    [Google Scholar]
  9. GVaccine Innovation Prioritisation Strategy (VIPS). 2023
    [Google Scholar]
  10. Popova G. Chen S.P. Liao S. Sadarangani M. Blakney A.K. Clinical perspective on topical vaccination strategies. Adv. Drug Deliv. Rev. 2024 208 115292 10.1016/j.addr.2024.115292 38522725
    [Google Scholar]
  11. Shi C. Peng X. Feng Y. Hydrogel surface/coating for smart drug delivery and medical devices. Gels 2024 10 9 592 10.3390/gels10090592 39330194
    [Google Scholar]
  12. Postigo Antonio Chapter 3-Vaccine research and development in Asia and the Pacific: strengthening partnerships among actors at the domestic and regional levels. From Lab to Jab: Improving Asia and the Pacific’s Readiness to Produce and Deliver Vaccines. Asian Development Bank Institute 2023 43 82
    [Google Scholar]
/content/journals/raddf/10.2174/0126673878398533250825152040
Loading
/content/journals/raddf/10.2174/0126673878398533250825152040
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test